Welcome to our dedicated page for Genflow Biosciences news (Ticker: GENFF), a resource for investors and traders seeking the latest updates and insights on Genflow Biosciences stock.
Genflow Biosciences Plc (GENFF) is a UK-headquartered biotechnology company with R&D facilities in Belgium, focused on longevity research and SIRT6-based gene therapies. This news page aggregates regulatory announcements and corporate updates related to Genflow’s scientific programs, intellectual property, and capital markets activity.
Readers can follow developments in Genflow’s gene therapy pipeline, including its 12‑month proof‑of‑concept clinical trial in aged dogs that evaluates a SIRT6‑centenarian gene therapy for age‑related decline. Company updates have highlighted dosing milestones, safety and tolerability observations in elderly dogs, and the design of blinded clinical assessments using biomarkers linked to sarcopenia, healthspan, and lifespan.
The news flow also covers Genflow’s plans to explore GF‑1002 in MASH (Metabolic Dysfunction‑Associated Steatohepatitis), reflecting its interest in metabolic and age‑related disorders. In addition, announcements detail progress in the company’s intellectual property strategy, such as European Patent Office publications recognizing the patentability of SIRT6 variant claims and the publication of a second European patent application titled “SIRT6 Variant for NASH.”
Investors and observers will also find information on equity issues, warrants, and voting rights, including share subscriptions, warrant terms, and total issued share capital figures disclosed for regulatory purposes. Notifications of major holdings and participation in sector events, such as the J.P. Morgan Healthcare Conference, appear in the same stream.
By reviewing the GENFF news page, users can see how Genflow communicates the evolution of its SIRT6 gene therapy platform, its animal health and human-focused programs, and its ongoing regulatory and capital markets disclosures.
Genflow Biosciences (LSE:GENF / OTCQB:GENFF) announced that the European Patent Office published its Euro‑PCT application in the EPO Bulletin on 15 October 2025, recognizing the patentability of claims for a SIRT6 variant patent (EP publication No. EP4338267; application No. 22808414.1; European publication EP4630038).
The publication places the application in the final pre‑grant phase under Article 67(3) EPC and activates provisional protection across participating EPO member states pending national validations. Genflow must bring the description into compliance with the claims in response to an Official Letter before the EPO will issue the intention to grant.
Genflow Biosciences (OTCQB:GENFF) provided an update on its Dog Aging (GF-1004) proof-of-concept trial testing a centenarian SIRT6 gene therapy in elderly dogs.
Repeat administration was completed in October 2025 in the randomized, controlled study of 28 beagles aged 10+, with no ill or adverse effects observed after the second dosing. The dogs enter a follow-up period expected to conclude in January 2026. The company highlighted potential animal-health commercial opportunities and continued partnership development while advancing to next-stage evaluation.
Genflow Biosciences (LSE:GENF / OTCQB:GENFF) announced on 9 October 2025 that it has terminated the previously announced subscription from 2 October 2025 and completed an Alternative Transaction raising gross proceeds of £440,000 via an allotment of 40,000,000 new ordinary shares at 1.1 pence per share. The shares were allotted to CEO Eric Leire, who will direct 35,454,546 shares to a consortium of existing shareholders and retain 4,545,454 shares.
Concurrent warrants will be issued one-for-one, exercisable at 1.2 pence for 24 months. Admission of the new shares is expected on or around 16 October 2025, after which total issued share capital and voting rights will be 493,547,942. The allotment used an employee-offer prospectus exemption under the UK Prospectus Regulation.
Genflow Biosciences (OTCQB:GENFF) has announced a significant equity issuance, raising £340,000 (before expenses) through the allotment of 40,000,000 new ordinary shares at 0.85 pence per share, representing a 35% discount to the October 1, 2025 bid price.
The transaction involves CEO Eric Leire subscribing to the shares under the employee offer exemption, who will then direct their issue to an institution for immediate sale to an identified purchaser. The purchaser will receive one-for-one warrants exercisable for 24 months at 1.2 pence. Upon admission, expected around October 9, 2025, the company's total issued shares will increase to 493,547,942.
Genflow Biosciences (OTCQB:GENFF) has successfully raised £340,000 through the issuance of 40,000,000 new ordinary shares at 0.85 pence per share. The transaction involves CEO Eric Leire initially subscribing to the shares under an employee offer exemption, who will then direct their issuance to an institution for immediate sale to an identified purchaser.
The purchaser will receive one-for-one warrants exercisable for 24 months at 1.2 pence. Upon admission of the new shares expected around October 9, 2025, the company's total issued shares will increase to 493,547,942. The funding will provide essential working capital and support ongoing dog studies while awaiting the Wallonia region grant's first payment.
Genflow Biosciences (OTCQB:GENFF) has reported its H1 2025 results, highlighting significant progress in both human and animal health programs focused on SIRT6 centenarian-based gene therapies. The company has strategically repositioned its GF-1002 therapy to target advanced MASH with fibrosis, addressing an underserved market segment.
Key financial metrics show cash reserves of £279,445 as of June 30, 2025, with administration expenses of £982,725, including R&D costs of £665,862. The company completed an equity fundraising of £868,698 (net) during H1 2025 and remains debt-free.
Genflow has expanded into ophthalmology and initiated a clinical trial for its GF-1004 therapy in dogs, partnering with Syngene CRO. The company is actively pursuing non-dilutive funding and has received support from the Wallonia Region for GF-1002 development.
Genflow Biosciences PLC (GENFF) reported a significant change in shareholding as Jonathan Mark Swann increased his voting rights in the company. The shareholder's position increased to 8.4% of total voting rights, up from the previous 7.01%, representing 36,588,550 voting rights.
The notification, filed on September 19, 2025, indicates the change occurred through direct acquisition of shares, with no financial instruments or indirect voting rights involved. The transaction was completed in London and reported in accordance with UK regulatory requirements.
["Increased stake by major shareholder indicates confidence in company", "Voting rights increased by 1.39 percentage points to 8.4%"]Genflow Biosciences (OTCQB:GENFF), Europe's only publicly listed longevity company, has filed for patent examination in China for its SIRT6 Variants targeting Non-Alcoholic Steatohepatitis (NASH). The patent application covers proprietary variants of the SIRT6 gene designed to address NASH, a severe progressive liver disease with limited treatment options.
This strategic move strengthens Genflow's global intellectual property portfolio and demonstrates its commitment to expanding its presence in one of the world's largest healthcare markets. The company aims to develop innovative SIRT6-based therapies to transform NASH treatment.
Genflow Biosciences (OTCQB:GENFF), Europe's only publicly listed longevity company, has signed two Confidential Disclosure Agreements (CDAs) with leading animal health companies. The agreements facilitate data exchange and discussions for potential collaborations leveraging Genflow's proprietary SIRT6-centenarian gene therapy platform in the companion animal market.
The company's ongoing GF-1004 Dog Aging study with beagles has reported no adverse events to date. These partnerships could accelerate Genflow's path to commercialization by providing access to global scale, regulatory expertise, and commercial infrastructure, potentially leading to licensing agreements in the animal health sector.
Genflow Biosciences (OTCQB:GENFF), Europe's only public longevity company, has reported positive progress in its Dog Aging study (GF-1004), testing a novel SIRT6-centenarian gene therapy. The trial involves 28 beagles aged 10+ years, with treatment administered in March 2025 showing no adverse effects.
The study aims to evaluate the therapy's potential in extending lifespan and improving quality of life in companion animals. Key objectives include validating safety, demonstrating benefits like reduced biological age, increased muscle strength, enhanced mitochondrial function, and improved coat quality. The five-month follow-up period will conclude in January 2026.
The successful completion of this trial could lead to a licensing agreement with a major Animal Health company and potentially unlock future applications in human longevity therapeutics.